Luca Busino, Ph.D.

faculty photo
Assistant Professor of Cancer Biology
Department: Cancer Biology

Contact information
421 Curie Blvd
705 BRB II/III
Philadelphia, PA 19104-6160
Lab: 215-746-2569
Education:
B.S. (Medical Biotechnology)
Università di Napoli, Federico II, 1999.
M.S. (Medical Biotechnology)
Università di Napoli, Federico II, 2001.
Ph.D. (Experimental Oncology)
European Institute of Oncology, 2008.
Post-Graduate Training
Visiting Scientist, Department of Pathology, New York University School of Medicine, 2006-2008.
Postdoctoral Fellow, Department of Pathology, New York University School of Medicine, 2008-2013.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF: Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426(6962): 87-91, November 2003.

Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, Draetta GF, Pagano M: SCFFbxl3 Controls the Oscillation of the Circadian Clock by Directing the Degradation of Cryptochrome Proteins. Science 316(5826): 900-4, May 2007.

Busino L, Millman SE, Kyratsous C, Scotto L, Basrur V, Hoffmann A, O’Connor O, Elenitoba- Johnson K, Pagano M: SCFFbxw7-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nature Cell Biology 14(4): 375-85, March 2012.

Choi J, Lee K, Ingvarsdottir K, Bonasio R, Saraf A, Florens L, Washburn MP, Tadros S, Green MR, Busino L: Loss of KLHL6 promotes DLBCL growth and survival via stabilization of the mRNA decay factor Roquin2. Nature Cell Biology 20(5): 586-596, April 2018.

Choi J, Saraf A, Florens L, Washburn MP, Busino L: PTPN14 regulates Roquin2 stability by tyrosine dephosphorylation. Cell Cycle Page: 1-13, September 2018.

Zhou N, Uzquiza AG, Zheng XY, Vogl D, Garfall AL, Bernabei L, Saraf A, Florens L, Washburn MP, Illendula A, Bushweller JH, Busino L: RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia 33(8): 2006-2021, August 2019.

Guillamot M, Ouazia D, Dolgalev I, Kourtis N, Dai Y, Corrigan K, Yeung S, Zea-Redondo L, Saraf A, Florens L, Washburn MP, Tikhonova AN, Gong Y, Tsirigos A, Park C, Barbieri C, Khanna K, Busino L*, Aifantis I* : The E3 ubiquitin ligase SPOP controls resolution of systemic inflammation by triggering MyD88 degradation. Nature Immunology 20(9): 1196-1207, September 2019 Notes: *BL and *AI co-last and co-corresponding authors.

Saffie R, Rolland DCM, Onder O, Basrur V, Elenitoba-Johnson KSJ, Capell BC, and Busino L: FBXW7 triggers degradation of KMT2D to favor growth of mature B-type malignant cells. Cancer Research 80(12): 2498-2511, June 2020 Notes: doi: 10.1158/0008-5472.CAN-19-2247. Epub 2020 Apr 29.

Nguyen KM, Busino L: Targeting the E3 ubiquitin ligases DCAF15 and Cereblon for Cancer Therapy. Seminar in Cancer Biology March 2020 Notes: pii: S1044-579X(20)30065-1. doi: 10.1016/j.semcancer.2020.03.007.

back to top
Last updated: 08/21/2020
The Trustees of the University of Pennsylvania
 
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.